NCT01320176

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Institut Pasteur · Industry
• Sex: All
• Age: 18 Years – 27 Years
• Healthy volunteers: Accepted

Summary

This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.

Conditions

• HIV

Interventions

Type	Name	Description
BIOLOGICAL	Investigational HIV vaccine dose A	The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
BIOLOGICAL	Investigational HIV vaccine dose B	The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2011-03-22
• Last updated: 2012-02-14

Locations

1 site across 1 country: Belgium